Member Info for TorquayFan

I may have missed something, but Scancell's presentation was Monday and the AACR concludes today. In the next day or two, are we expecting any further details of the presentation that was given and some further publicity? Or is that it?

Thanks.

Hi Violin. Wolf ! No Scancell are not crying that.

Honestly this - ""The "investment community" having just listened to the presentation aren't prepared to invest now"" is just wailing. Did you expect Pharma at AACR to rush up to the podium waving cheque books?

Nothing is 'unfortunate' - we have been offered timelines for announcements and a commitment to those timelines.

We still have our 'make' year and we are just 1/3 of the way through it! ATB

Ah yes. Thanks Violin . . .

That's very interesting Bermuda and of course, it will be good to have that awareness of Scancell in the AACR.

At the time that the USA trial was being discussed, I used to chat about Scancell to a Friend from the USA who knew KF well, (having had half his scalp removed with KF as his Consultant). This Guy was still in touch with KF at that time and though I've lost touch, I understand he still thrives.

The reasons the US SCIB1 trial never went ahead escape me atm, in the fug of a long Scancell history!

Dalester - no not annoying but to this luddite irrelevant. I think the BB is more helpful when based on posts by people. And I'd also trust Scancell to know more about ithe science than AI. That's all.

Violin/Ruck. Yes 14 posts have disappeared from the 'count' and thanks whoever for that. That's what the 'filter' is for, as I suggested aeons ago. Let's hope that's the last we see of that nuisance.

Now IMHO, it'd be good to see all AI posts removed too, (but from a luddite!). ATB

Marcus in 19545 observes :-

"So 5 out of 23 patients in scib-1 had a complete response, 21.739 %

70% demonstrated a T Cell response and of those 94% had disease control

16mins"

https://www.youtube.com/watch?v=8ARuWSMNNTM&ab_channel=InvestorMeetCompany

Thanks again.

I totally agree with that header Ruck !!

Marcus over there has posted a link. I found the Presentation enthralling. I am convinced we are in the best hands business wise with our 'new' CEO and congratulations to him, Sath, Mandeep and all Team Scancell for that informative, comprehensive and very exciting update.

Here's the link

https://www.youtube.com/watch?v=8ARuWSMNNTM&ab_channel=InvestorMeetCompany

Noting that there may be more feedback as Team Scancell answer more questions personally.

Thank you Marcus - being 'ere I'm the early bird !

Never to forget that without the genius of Prof. Lindy, no-one at all could be even mooting the realistic possibility of a 'cancer free future'.

Brilliant !

Nice one over there from Marcus - "PharmaJet will also be delivering a pre-conference presentation entitled Navigating the Immune System starts with Precise Delivery, during the Vaccine Delivery Session on April 21, 2025, from 2:00 – 5:00 PM in Room 202A

PharmaJet® Presents Partner Data Demonstrating that Needle-free Delivery Boosts Immune Response of DNA and Novel Therapeutic Cancer Vaccines April 23, 2025, at 12:25 PM ET, Room 206"

Already mentioned but worth seeing again.

Ivy started an interesting discussion over there (19139 onwards) - "PharmaJet® Presents Partner Data Demonstrating that Needle-free Delivery Boosts Immune Response of DNA and Novel Therapeutic Cancer Vaccines"

Bermuda kindly provided - https://www.businesswire.com/news/home/20250417764076/en/PharmaJet-Presents-Partner-Data-Demonstrating-that-Needle-free-Delivery-Boosts-Immune-Response-of-DNA-and-Novel-Therapeutic-Cancer-Vaccines

"World Vaccine Congress 2025 presentation, What if Delivery Is the Missing Link in Cancer Immunotherapy? Insights from DNA Cancer Vaccine Trials Using Needle-Free Injection Delivery, will highlight how PharmaJet’s Precision Needle-free delivery has been successfully incorporated into multiple pharmaceutical development programs. PharmaJet needle-free technology induces immune responses and clinical benefits according to partner data from DNA therapeutic vaccine studies in difficult to treat cancer patient populations. The presentation is scheduled for April 23, 2025, at 12:25 PM ET, Room 206 at the Walter E. Washington Convention Center, Washington, D.C. " . . . . (more in the link).

With Pharmajet, Scancell are at the cutting edge of vaccine delivery. Good to see Scancell getting these mentions . . . .

Fair enough C11, but not to forget that through recent years, Prof. Lindy had been busy gathering together the team we now have. Hopefully, the arrival of M. L'Huillier as the finishing touch, was well timed. It's great that he's here now and Prof. Lindy can orchestrate the science again, with full attention.

With 4 data raedouts due this year, I guess they got the timing of the team development right.

Thanks for the ProActive link Bermuda. - In 8 minutes, CEO twice emphasises his determination to meet timelines - let's hope that works out!

The timelines are - mid 2025 for Scope cohort 1 (SCIB1) AND cohort 3 (iSCB1+)

- 2nd half 2025 readouts for 'Modify Phase 2'

- end 2025 Scope cohort 4 with CVLP

And as EE says, CEO expresses the will to take SC134 further . . . .

Thanks to Inan who seems beat LSE to it !

RNS now here too and the news is, IMHO, 'formidable'.

Phil L'Huillier, Chief Executive Officer, Scancell, commented: "We are delighted to announce our partnership with the CVLP. This partnership offers melanoma patients in the UK faster access to our developmental cancer vaccine, iSCIB1+, that we see is bringing long term immune control of the tumours to these advanced melanoma patients. It additionally underscores the potential benefit of iSCIB1+ to advanced stage melanoma patients and the longer-term market opportunity. Data from the SCOPE study will allow us to implement a robust development plan for the next phase towards registration in 2026."

NHS national cancer director Professor Peter Johnson said: "Skin cancer can have a devastating impact, and we know that cancer vaccines have the potential to revolutionise cancer care for patients in this country and across the world - and to save more lives. It's incredibly exciting that the NHS is expanding its world-leading programme so more patients with different types of cancer could benefit from the development of new vaccines that could stop their cancer coming back."

The SCOPE study will enrol over 140 patients across four cohorts. Reported phase 2 clinical data from 25 patients in cohort 1 receiving the first-generation vaccine SCIB1 i.m. in combination with checkpoint inhibitors, ipilimumab and nivolumab, have shown 80% progression free survival (PFS) and 20% complete response rate (CR). Cohort 3, investigating the next generation iSCIB1+i.m. in combination with ipilimumab and nivolumab, has now completed recruitment of 45 patients and the fourth cohort, to be recruited in partnership with CVLP, will evaluate intradermal administration of iSCIB1+

Data from all study cohorts in the SCOPE trial will inform the design of the upcoming randomised trial, which is planned for in H2 2026, either by Scancell or in partnership. Clinical data from SCIB1 in cohort 1 and iSCIB1+ in cohort 3 is expected around mid-2025, while clinical data from iSCIB1+ in cohort 4, following the partnership with CVLP, is expected late 2025.

Melanoma is the fifth most common cancer in the UK, accounting for around 4% of all new cancer cases. While immunotherapy is a standard treatment for advanced melanoma patients, only about half of patients respond well, leaving the rest at risk of disease progression and metastases. iSCIB1+ precisely targets activated antigen presenting cells via CD64 and effectively activates high-avidity T cells, leading to a potent, lasting immune response thereby creating an immune memory that may prevent the cancer from recurring. As a part of the trial, patient tissue type or "HLA" type will need to be determined by using a blood test to look for the presence or absence of genes which control how the immune system works.

Dr Nermeen Varawalla, Chief Medical Officer, Scancell, said: "Cancer vaccines have the potential to transform immunotherapy, redefine treatment options and ultimately save lives. Recent clinical data has demonstrated that our potent, tumour-targeted 'off-the-shelf' cancer vaccine delivers strong efficacy, with the potential for meaningful long-term survival benefits in patients with advanced metastatic melanoma. Our partnership with the CVLP will give patients expedited access to this landmark study and is an important step in accelerating the clinical development of this important new treatment."

Partnership with NHS Cancer Vaccine Launch Pad Enabling

Fast-Tracked Access for Melanoma Patients

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapy products for the treatment of multiple cancers, announces a partnership with the NHS Cancer Vaccine Launch Pad (CVLP) to fast-track access for NHS patients into the fourth cohort of the Company's Phase 2 clinical SCOPE study. This cohort will evaluate intradermal administration of Scancell's iSCIB1+, potent, targeted "off-the-shelf" Immunobody® second generation DNA cancer vaccine, in patients with advanced unresectable melanoma receiving standard of care immunotherapy treatments.

The CVLP, launched in May 2024, is a world-leading NHS trial "matchmaking" service to help find new life-saving treatments. NHS Hospitals across the country will be able to take part in this transformational study, with eligible patients from around the UK being referred to a participating NHS site. The partnership is being coordinated and run by the Southampton Clinical Trials Unit, with the first patients expected to be referred from May. Scancell is the first British company to join the CVLP, and iSCIB1+ is the first DNA vaccine to be part of this initiative.

Good work M8 - thanks very much. RNS today - no doubt !

Thanks to the Posters yesterday too - this link up to the NHS CVLP could be a real boost.

ATB

Yes thanks C11 - no problem . . .

Nice one from Marcus 18597 over there :-

https://www.genengnews.com/topics/cancer/cancer-vaccines-improve-their-aim/

Another bang on the 'off the shelf is ok' drum - more please . . it may be the same piece as published elsewhere recently. It's the 3rd chapter down . . . .

Thanks Marcus.